Patents Assigned to Aeras
  • Patent number: 12292937
    Abstract: Techniques for a network-accessible cognitive automation platform for a self-driving application are provided. The platform includes a cognitive operating system, which includes a data crawler configured to discover and extract data stored in internal systems and external third-party systems, a data processing engine configured to cleanse, correlate, link, etc., transactional and unstructured data, and a cognitive data layer (CDL) configured to process the transformed crawled data with various models and algorithmic libraries of metrics, trends, and metadata to identify a root cause of an issue and prescribe actions to mitigate or overcome risks related to the issue. A cognitive development kit is configured to build a specific skill application on top of the cognitive operating system, the specific skill application generating recommendations, actions, and predictions. A search processor and GUI are configured to perform a search request of the data in the CDL and display the results in the GUI.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: May 6, 2025
    Assignee: Aera Technology, Inc.
    Inventor: Shariq Mansoor
  • Patent number: 12281567
    Abstract: A method for detecting leaks in a casing involves running a fiber-optic distributed temperature sensing cable into a well casing to obtain at least one trace in real time. The method includes thermally conditioning the well by inert gas injection and utilizing a trace to calculate moving average temperature gradients at predetermined intervals, determine the mean and standard deviation of these gradients, and establish a lower control limit based on the mean and standard deviation. By identifying any moving average temperature gradient below the lower control limit, the method enables the determination of the depth associated with leaks in the casing.
    Type: Grant
    Filed: October 4, 2024
    Date of Patent: April 22, 2025
    Assignee: Aera Energy LLC
    Inventor: Rickey Sullivan
  • Patent number: 10789277
    Abstract: The present invention includes a method, apparatus, and a system for creating business navigation maps comprising a host module linked to at least one computer, and at least one data base and/or data storage device, the host module being adapted to receive data point markers about at least one data point of interest to a user and including a data input link for receiving information about at least one data point of interest, a first logic processing module programmed to associate at least one data point of interest with at least one business report, wherein the logic processing module uses predefined criteria to tag the at least one data point of interest as relevant to the at least one business report; and a database module, the database module being adapted to store and obtain the at least one data point of interest, data point markers, and the at least one business report.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 29, 2020
    Assignee: Aera Technology, Inc.
    Inventor: Shariq Mansoor
  • Publication number: 20180365312
    Abstract: The present invention includes a method, apparatus, and a system for creating business navigation maps comprising a host module linked to at least one computer, and at least one data base and/or data storage device, the host module being adapted to receive data point markers about at least one data point of interest to a user and including a data input link for receiving information about at least one data point of interest, a first logic processing module programmed to associate at least one data point of interest with at least one business report, wherein the logic processing module uses predefined criteria to tag the at least one data point of interest as relevant to the at least one business report; and a database module, the database module being adapted to store and obtain the at least one data point of interest, data point markers, and the at least one business report.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Applicant: Aera Technology, Inc.
    Inventor: Shariq Mansoor
  • Patent number: 9939149
    Abstract: Modern steam generators typically include a radiant section and a convection section. Due to differing performance requirements of the radiant and convection sections, the radiant section often has a round cross-section, while the convection section often has a rectangular cross-section. Previous designs utilized a target wall to effect the transition. An angled transition section is disclosed herein that substantially eliminates the target wall and/or the reverse target and provides a corresponding improvement in steam generator efficiency.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: April 10, 2018
    Assignees: PCL Industrial Services, Inc., Aera Energy LLC
    Inventors: Garry Loren Barker, Mark Elmer Pittser, Zachary Mark Smith
  • Patent number: 9926346
    Abstract: Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: March 27, 2018
    Assignees: Aeras, Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: John Fulkerson, Michael Brennan, Kamalakannan Velmurugan, Camille Locht
  • Patent number: 9610343
    Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 4, 2017
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Tom Han Jin, Eric I-Fu Tsao
  • Publication number: 20150291669
    Abstract: Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.
    Type: Application
    Filed: April 16, 2012
    Publication date: October 15, 2015
    Applicants: Aeras Global TB Vaccine Foundation, Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: John Fulkerson, Michael Brennan, Kamalakannan Velmurugan, Camille Locht
  • Publication number: 20150034024
    Abstract: Modern steam generators typically include a radiant section and a convection section. Due to differing performance requirements of the radiant and convection sections, the radiant section often has a round cross-section, while the convection section often has a rectangular cross-section. Previous designs utilized a target wall to effect the transition. An angled transition section is disclosed herein that substantially eliminates the target wall and/or the reverse target and provides a corresponding improvement in steam generator efficiency.
    Type: Application
    Filed: September 12, 2013
    Publication date: February 5, 2015
    Applicants: Aera Energy LLC, PCL Industrial Services, Inc.
    Inventors: Garry Loren Barker, Mark Elmer Pittser, Zachary Mark Smith
  • Patent number: 8728492
    Abstract: Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the Plasmodium falciparum circumsporozoite protein (CSP) known to contain CD4 and CD8 T cell epitopes, and include both epitopes from highly variable and highly conserved regions of CSP.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: May 20, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Avigdor Shafferman, Anat Zvi, John Fulkerson, Jerald C. Sadoff
  • Patent number: 8658136
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: February 25, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Patent number: 8609402
    Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: December 17, 2013
    Assignees: Aeras Global TB Vaccine Foundation, Crucell Holland B.V
    Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Rado{hacek over (s)}evic
  • Publication number: 20130224242
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: April 8, 2013
    Publication date: August 29, 2013
    Applicant: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.
  • Patent number: 8414884
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 9, 2013
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Patent number: 8361482
    Abstract: A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The vaccine is protective against active Mtb infection both pre- and post-exposure to Mtb, and thus prevents disease symptoms due to the recurrence of a latent Mtb infection.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: January 29, 2013
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Avigdor Shafferman, Anat Zvi, Naomi Ariel, John Fulkerson, Roaggai Sun, Rosemary Chang, Jerald C. Sadoff
  • Patent number: 8202723
    Abstract: Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: June 19, 2012
    Assignees: Crucell Holland B.V., Aeras Global TB Vaccine Foundation
    Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Rado{hacek over (s)}evic
  • Patent number: 8053568
    Abstract: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: November 8, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: David Hone, John Fulkerson, Jerald C. Sadoff, David Onyabe, Michele Stone
  • Patent number: 8043857
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: October 25, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Patent number: 8012467
    Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: September 6, 2011
    Assignees: Crucell Holland B.V., Aeras Global TB Vaccine Foundation
    Inventors: Menzo J. E. Havenga, Ronald Vogels, Jerald Sadoff, David Hone, Yasir A. W. Skeiky, Katarina Radosevic
  • Patent number: 7935354
    Abstract: A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: May 3, 2011
    Assignees: Aeras Global TB Vaccine Foundation, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mario Alberto Flores-Valdez, Gary K. Schoolnik, Michel Klein, Jerald C. Sadoff, David Hone